“We are pleased to present our inaugural ESG Summary Report, in which our aim is to address the diverse interests of our multiple stakeholders”, said
“As part of our commitment to deliver information to our stakeholders on the topics that are most material to our industry and our company, we are aligning with the
To obtain a copy of the report, please click here.
About
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under the captions “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended
Investor and Media Contact
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
Source:
2022 GlobeNewswire, Inc., source